Navigation Links
Caffeic acid inhibits colitis in a mouse model -- is a drug-metabolizing gene crucial?
Date:5/26/2009

This release is available in Chinese.

Researchers at Iowa State University have found that increased expression of a form of cytochrome P-450 (CYP4B1) is a key marker of inhibition of colitis in mice by caffeic acid, an anti-inflammatory antioxidant compound widely distributed in foods. The results, which appear in the June 2009 issue of Experimental Biology and Medicine, implicate CYP4B1, a form of cytochrome P450 previously found to be associated with resolution of allergic inflammation in another model. The normalization of CYP4B1 by caffeic acid treatment was associated with significant lessening of colitic damage, assessed by examining colon histopathology. In comparison with rutin, an anti-inflammatory flavonoid and hypoxoside extract, a botanical known as African potato previously shown to protect against colitis, all three compounds had anti-inflammatory effects, suppressing myeloperoxidase, IL-17 and iNOS and increasing IL-4, known factors associated with inflammation responses. But only caffeic acid protected against the dextran sulfate sodium induced colitis. Its novel mechanism related to CYP4B1 is being studied further. The research team, Zhong Ye, a graduate student in Toxicology, along with Microbiology graduate students Zhiping Liu and Abigail Henderson, Visiting Scientist Kwangwon Lee, Korea University, Dr. Michael Wannemuehler, Veterinary Microbiology, Dr. Jesse Hostetter, a veterinary pathologist, and Dr. Suzanne Hendrich, Toxicologist and Nutritionist, performed studies in 8 week old mice fed the various dietary components and then exposed to dextran sulfate sodium in a mildly irritating dose to induce colitis. Dr. Hendrich noted that "this study of caffeic acid will help us to advance studies of botanicals and plant foods with respect to their ability and mechanisms of inhibiting colitis, and perhaps colon cancer, because colitis increases risk for this disease".

In summary, normalization of expression of CYP4B1, a drug metabolizing enzyme possibly related to reversal of inflammatory damage was a hallmark of the efficacy of caffeic acid, a component found widely in plant foods in the human diet, to inhibit intestinal tissue damage in a mouse model commonly used to simulate colitis. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine said "The article by Hendrich and colleagues may help in the future design of more effective treatments to prevent or diminish colitis".


'/>"/>

Contact: Dr. Suzanne Hendrich
shendric@iastate.edu
515-294-4272
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Herpes drug inhibits HIV in patients infected with both viruses
2. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
3. New genetic markers for ulcerative colitis identified, researchers report in Nature Genetics
4. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
5. A new mouse model provides insight into genetic neurological disorders
6. Diminuendo -- New mouse model for understanding cause of progressive hearing loss
7. Mouse model provides a new tool for investigators of human developmental disorder
8. CSHL team develops mouse models of leukemia that predict response to chemotherapy
9. Brain building: Study shows brain growth tied to cell division in mouse embryos
10. A worm-and-mouse tale: B cells deserve more respect
11. Salk researchers develop novel glioblastoma mouse model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
Breaking Biology Technology: